01
Cash & equivalents increased 487.6%
Cash & equivalents changed +487.6% from the comparable as-filed period.
$16.4M→$96.3MComparable → current
· Pharmaceutical Preparations
RESEARCH SNAPSHOTSPRUCE BIOSCIENCES, INC.'s latest supported as-filed period reports revenue of $0. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed +487.6% from the comparable as-filed period.
Debt changed +1951.9% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Net income changed -685.1% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
SPRB · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-345876SEC ↗8-KAug 12, 2026Period Aug 12, 20260001193125-26-345874SEC ↗4Jul 29, 2026Period Jul 27, 20260001910132-26-000007SEC ↗8-KJul 27, 2026Period Jul 27, 20260001193125-26-316928SEC ↗4Jul 9, 2026Period Jun 30, 20260001903669-26-000006SEC ↗4May 26, 2026Period May 21, 20260001238403-26-000002SEC ↗4May 26, 2026Period May 21, 20260001822557-26-000002SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Jul 27, 2026Filed Jul 29, 2026 | Quartel Adrian WChief Medical Officer | Grant Or AwardDirect | 13,000 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Operating income changed -513.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Research & development changed +2928.6% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +1231.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001240122-26-000002